Effect of systemic lupus erythematosus (SLE) treatment drugs on GI-101A breast tumor cell growth.
The effect of systemic lupus erythematosus (SLE) treatment drugs on PKC (protein kinase C) activity and cell growth was studied using GI-101A breast tumor cells. Both hydroxychloroquine (HCQ) and prednisone treatments significantly increased the PKC activity in GI-101A cells after 60 min. Treatment of cells with a combination of HCQ/prednisone also produced the highest increase in PKC activity following 60 min incubation. When the GI-101A cells were treated with the same drugs, HCQ (10 ng/ml) prednisone (10 ng/ml) and HCQ/prednisone combination (10 ng/ml of each), for 72 hr the total PKC activity in the cells was significantly elevated and consequently the GI-101A cell growth was stimulated. As a result of drug induced cell growth stimulation the total number of cells in the treatment groups increased significantly compared to the non-treated controls. Interestingly HCQ and prednisone treatment induced cell growths were completely blocked by PKC specific inhibitor chelerythrine (50 microM). Our results suggest that HCQ and prednisone treatment can induce GI-101A cell growth via activating PKC.
Fernandez
Y
Y
Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Ft Lauderdale, FL 33328, USA.
Ramakrishnan
R
R
Rathinavelu
A
A
D001943:Breast Neoplasms / Q000473:pathology*; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D006886:Hydroxychloroquine / Q000494:pharmacology*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011241:Prednisone / Q000494:pharmacology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D014407:Tumor Cells, Cultured
D004791:Enzyme Inhibitors; D006886:Hydroxychloroquine; D011493:Protein Kinase C; D011241:Prednisone